相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
Ranjana H. Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation
Santiago Montes-Moreno et al.
MODERN PATHOLOGY (2012)
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study
Robert Pirker et al.
LANCET ONCOLOGY (2012)
Differential regulation of miR-21 and miR-146a by Epstein-Barr virus-encoded EBNA2
P. Rosato et al.
LEUKEMIA (2012)
Epstein-Barr virus latent membrane protein-1 protects B-cell lymphoma from rituximab-induced apoptosis through miR-155-mediated Akt activation and up-regulation of Mcl-1
Joo Hyun Kim et al.
LEUKEMIA & LYMPHOMA (2012)
Src Kinase and Syk Activation Initiate PI3K Signaling by a Chimeric Latent Membrane Protein 1 in Epstein-Barr Virus (EBV) plus B Cell Lymphomas
Olivia Hatton et al.
PLOS ONE (2012)
Regulation, Role, and Targeting of Akt in Cancer
Michael A. Davies
JOURNAL OF CLINICAL ONCOLOGY (2011)
Novel Therapeutics for Aggressive Non-Hodgkin's Lymphoma
Daruka Mahadevan et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
Timothy A. Yap et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma of the Elderly: What We Know So Far
Jorge J. Castillo et al.
ONCOLOGIST (2011)
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
Jonathan W. Friedberg et al.
BLOOD (2010)
High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy
Sverker Hasselblom et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
The PI3K Pathway As Drug Target in Human Cancer
Kevin D. Courtney et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Epstein-Barr virus positive diffuse large B-cell lymphoma of the elderly
Hannah H. Wong et al.
LEUKEMIA & LYMPHOMA (2009)
Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma
M. Crump et al.
ANNALS OF ONCOLOGY (2008)
EBV latent membrane protein 1 activates Akt, NFκB, and Stat3 in B cell lymphomas
Kathy H. Y. Shair et al.
PLOS PATHOGENS (2007)
The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma
Sarah Park et al.
BLOOD (2007)
Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma
Michael J. Robertson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival
Shahab Uddin et al.
BLOOD (2006)
Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma
Martina Rudelius et al.
BLOOD (2006)
Perturbations of the AKT signaling pathway in human cancer
DA Altomare et al.
ONCOGENE (2005)
Prognostic significance of activated Akt expression in melanoma: A clinicopathologic study of 292 cases
DL Dai et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma
S Yamamoto et al.
CLINICAL CANCER RESEARCH (2004)
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy
HG Wendel et al.
NATURE (2004)
Prognostic relevance of activated Akt kinase in node-negative breast cancer: a clinicopathological study of 99 cases
KJ Schmitz et al.
MODERN PATHOLOGY (2004)
Epstein-Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras/PI3K/Akt pathway
T Portis et al.
ONCOGENE (2004)
Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage
O David et al.
CLINICAL CANCER RESEARCH (2004)
Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable
YH Min et al.
LEUKEMIA (2003)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
B Coiffier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
分享论文
